49 Wealth Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

49 Wealth Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$155K	Sell	66,401 -4,510	-6%	-$11.6K	0.01%	191
2025 Q4	$95.7K	Buy	70,911 +42,719	+152%	+$62.2K	0.01%	193
2025 Q3	$42.6K	Buy	28,192 +6,646	+31%	+$9.96K	﹤0.01%	194
2025 Q2	$25K	Sell	21,546 -23,967	-53%	-$31.6K	﹤0.01%	176
2025 Q1	$72.4K	Buy	45,513 +18,874	+71%	+$40.7K	0.01%	181
2024 Q4	$80.7K	Buy	26,639 +4,081	+18%	+$13.4K	0.01%	166
2024 Q3	$83K	Buy	22,558 +10,145	+82%	+$36.9K	0.01%	172
2024 Q2	$52K	Buy	12,413 +1,751	+16%	+$19.6K	0.01%	152
2024 Q1	$172K	Buy	+10,662	New	+$147K	0.04%	120

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

49 Wealth Management's ZNTL Position: Q1 2026 in Review

49 Wealth Management reduced its Zentalis Pharmaceuticals (ZNTL) stake by 6.4% in Q1 2026, selling an estimated $11.6K and leaving 66,401 shares worth $155K. The position accounts for 0.01% of the portfolio, ranked #191.

49 Wealth Management first reported a position in ZNTL in Q1 2024 and has held it in 9 quarters since. The position peaked at $172K in Q1 2024. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

49 Wealth Management held 66,401 shares of Zentalis Pharmaceuticals worth $155K as of Q1 2026.
49 Wealth Management sold 4,510 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $11.6K.
Zentalis Pharmaceuticals made up 0.01% of 49 Wealth Management's portfolio in Q1 2026, its #191 holding.
49 Wealth Management first reported a position in Zentalis Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
49 Wealth Management's Zentalis Pharmaceuticals position peaked at $172K in Q1 2024.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on 49 Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.